Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'

Affiliations

¹ International Drug Development Institute, Louvain-la-Neuve, Belgium Dendrix Research, Sao Paulo, Brazil everardo.saad@iddi.com.
² International Drug Development Institute, Louvain-la-Neuve, Belgium Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Hasselt University, Diepenbeek, Belgium.

Free article

Comment

E D Saad et al. Ann Oncol. 2016 Aug.

Free article

. 2016 Aug;27(8):1653.

doi: 10.1093/annonc/mdw196. Epub 2016 May 6.

¹ International Drug Development Institute, Louvain-la-Neuve, Belgium Dendrix Research, Sao Paulo, Brazil everardo.saad@iddi.com.
² International Drug Development Institute, Louvain-la-Neuve, Belgium Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Hasselt University, Diepenbeek, Belgium.

No abstract available

Comment on

Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.
Saad ED, Buyse M. Saad ED, et al. Ann Oncol. 2016 Mar;27(3):373-8. doi: 10.1093/annonc/mdv562. Epub 2015 Nov 16. Ann Oncol. 2016. PMID: 26578738 Review.
Reply to 'Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents' by Saad and Buyse.
van Halteren HK. van Halteren HK. Ann Oncol. 2016 Aug;27(8):1652-3. doi: 10.1093/annonc/mdw189. Epub 2016 May 30. Ann Oncol. 2016. PMID: 27241134 No abstract available.